id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-274401-pjyvg53w	Hrkach, Jeff	From micro to nano: evolution and impact of drug delivery in treating disease	2020-05-08		.txt	text/plain	2055	100	38	An early wave featured injectable (i.e., intramuscular, subcutaneous) biodegradable polymeric microspheres to control drug release profiles for peptides and small molecules (e.g., Lupron Depot®, Risperdal Consta®). With these early successes for microspheres, research shifted to exploring systemic delivery by intravenous injection, which required smaller particle sizes and modified surface properties (e.g., PEGylation) to enable long circulation times. These new innovations resulted in the nanoparticle medicines Doxil® and Abraxane®, designed to improve the therapeutic index of cytotoxic cancer agents by decreasing systemic exposure and delivering more drug to tumors. In 2003, the FDA approved Risperdal Consta®, a controlled release form of risperidone encapsulated in PLG microspheres that enabled dosing once every 2 weeks by intramuscular injection. The many successes of controlled release microsphere-based medicines led innovators to explore the potential of drug delivery for systemic administration to reach specific sites of disease, with particular interest in targeting tumors for treating cancer.	./cache/cord-274401-pjyvg53w.txt	./txt/cord-274401-pjyvg53w.txt